Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, Open-label, Randomized, Two Part, Three-Period, Two-Sequence, Cross-over Study to Investigate the Relative Bioavailability of a Tablet Formulation Compared to Powder-in-Capsule of M7583 Including a Food Effect Evaluation for the Tablet in Healthy Volunteers

Next Previous
Trial Profile

Phase I, Open-label, Randomized, Two Part, Three-Period, Two-Sequence, Cross-over Study to Investigate the Relative Bioavailability of a Tablet Formulation Compared to Powder-in-Capsule of M7583 Including a Food Effect Evaluation for the Tablet in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TL 895 (Primary)
  • Indications B-cell lymphoma
  • Focus Pharmacokinetics
  • Sponsors Merck KGaA

Most Recent Events

  • 15 Jun 2023 Results assessing the pharmacokinetics and bruton tyrosine kinase occupancy pharmacodynamics of TL-895 in fasted and fed states, and effect of acid reducingagents on TL-895 PK and PD in fed healthy subjects, presented at the 28th Congress of the European Haematology Association.
  • 15 Jun 2023 Results by deriving data from this and other study developing and validating a mechanistic absorption and pharmacokinetic model of covalent Btk inhibitor Tl- 895 to evaluate the influence of food and acid reducing agents, presented at the 28th Congress of the European Haematology Association
  • 22 Jan 2018 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top